```html

Kawasaki‑like Syndrome (Multisystem Inflammatory Syndrome in Children – MIS‑C)

Overview

Multisystem Inflammatory Syndrome in Children (MIS‑C) is a rare but serious condition that typically appears 2‑6 weeks after infection with SARS‑CoV‑2, the virus that causes COVID‑19. It shares many clinical features with classic Kawasaki disease—hence the term “Kawasaki‑like syndrome.” MIS‑C is characterized by widespread inflammation that can affect the heart, blood vessels, gastrointestinal tract, skin, and nervous system.

Who it affects: Although it can occur in children of any age, the median age is 8–11 years, older than the usual age range for classic Kawasaki disease (under 5 years). Both boys and girls are affected, with a slight male predominance (≈ 55 %). The condition has been reported worldwide, but the highest incidence has been seen in regions with high COVID‑19 transmission.

Prevalence: As of mid‑2024, the U.S. Centers for Disease Control and Prevention (CDC) has recorded > 9,000 MIS‑C cases in the United States, translating to roughly 2–3 cases per 100,000 children under 21 years of age. The incidence peaks roughly 4–6 weeks after a community surge in COVID‑19 cases.<sup>1</sup>

Symptoms

Symptoms can develop rapidly and often involve multiple organ systems. The following list reflects the most commonly reported features (≥ 30 % of cases) and the less frequent but clinically important findings.

General / Constitutional

• Fever lasting ≥ 24 hours – usually high (≥ 38.5 °C) and persistent.
• Chills, fatigue, and malaise.
• Headache or neck pain.

Cardiovascular

• Chest pain or tightness.
• Rapid heart rate (tachycardia) out of proportion to fever.
• Low blood pressure or shock (hypotension).
• Myocarditis (inflammation of heart muscle) – can cause reduced ejection fraction.
• Coronary artery dilation or aneurysms (similar to Kawasaki disease).

Gastrointestinal

• Abdominal pain, often severe.
• Nausea, vomiting, or diarrhea.
• Loss of appetite.

Dermatologic / Mucocutaneous

• Rash (maculopapular, erythematous, or confluent).
• Red, cracked lips and “strawberry” tongue.
• Conjunctival injection (red eyes without discharge).
• Swelling of the hands/feet (often with desquamation after 2–3 days).

Respiratory

• Cough, shortness of breath.
• Upper airway congestion or sore throat.

Neurologic

• Confusion or altered mental status.
• Headache and photophobia.
• Seizures (rare, but reported).

Laboratory clues

• Elevated inflammatory markers: C‑reactive protein (CRP), ferritin, ESR.
• Neutrophilia with lymphopenia.
• Elevated cardiac enzymes (troponin, BNP/NT‑proBNP).
• Coagulopathy: high D‑dimer, low platelets in later stages.

Causes and Risk Factors

The exact pathophysiology of MIS‑C remains under investigation, but current evidence points to an abnormal immune response to SARS‑CoV‑2.

Proposed mechanisms

• Post‑viral hyperinflammation: A delayed, dysregulated immune response that releases large amounts of cytokines (“cytokine storm”).
• Molecular mimicry: Viral proteins may share epitopes with host tissues, leading to auto‑antibody production.
• Endothelial injury: Direct viral damage and immune‑mediated inflammation of blood vessels contribute to cardiac and vascular complications.

Risk factors

• Prior SARS‑CoV‑2 infection (most often confirmed by PCR or serology).
• Older children and adolescents (median age 8–11 y).
• Male sex (≈ 55 % of cases).
• Certain ethnic groups—higher rates reported in Black, Hispanic, and South Asian children in the U.S. and UK.<sup>2</sup>
• Underlying immune dysregulation (e.g., autoimmune disease) may increase susceptibility, though most children with MIS‑C were previously healthy.

Diagnosis

MIS‑C is a clinical diagnosis that requires a combination of epidemiologic, laboratory, and imaging criteria. The CDC and WHO have published overlapping case definitions; most hospitals use a hybrid approach.

Key diagnostic criteria (CDC)

1. Age < 21 years.
2. Fever ≥ 38.0 °C for ≥ 24 hours.
3. Laboratory evidence of inflammation (CRP, ESR, ferritin, etc.).
4. Evidence of clinically severe illness requiring hospitalization.
5. Multisystem (≥ 2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological).
6. Positive SARS‑CoV‑2 test (PCR, antigen, or serology) OR known exposure to a COVID‑19 case within the preceding 4 weeks.

Laboratory tests

• Complete blood count (CBC) – often shows neutrophilia, lymphopenia, and thrombocytopenia (later).
• CRP, ESR, ferritin – markedly elevated.
• Cardiac markers – troponin, BNP/NT‑proBNP.
• Coagulation profile – PT/INR, aPTT, D‑dimer, fibrinogen.
• Liver enzymes (AST/ALT) and renal function (creatinine) – may be abnormal.
• SARS‑CoV‑2 PCR and serology.

Imaging and other studies

• Echocardiogram: First‑line cardiac assessment; looks for ventricular dysfunction, pericardial effusion, and coronary artery changes.
• Chest X‑ray or CT: Evaluate pulmonary infiltrates or pleural effusion.
• Abdominal ultrasound/CT: May reveal ileitis, ascites, or mesenteric adenitis.
• Electrocardiogram (ECG): Detect arrhythmias, ST‑segment changes.

Differential diagnosis

Because MIS‑C mimics many other conditions, clinicians must rule out:

• Kawasaki disease (especially in younger children).
• Septic shock or bacterial toxic shock syndrome.
• Acute COVID‑19 infection with severe respiratory involvement.
• Rheumatic fever, systemic lupus erythematosus, or other vasculitides.

Treatment Options

Prompt treatment improves outcomes and reduces the risk of cardiac sequelae. Management is multidisciplinary, involving pediatric infectious disease, cardiology, rheumatology, and intensive‑care teams.

Hospital admission

All children meeting MIS‑C criteria should be admitted, many to a pediatric intensive care unit (PICU) for close monitoring of cardiac function and hemodynamics.

Immunomodulatory therapy

• Intravenous immunoglobulin (IVIG): 2 g/kg single dose is first‑line, mirroring Kawasaki treatment. Reduces fever and inflammation in > 80 % of cases.<sup>3</sup>
• Corticosteroids: Methylprednisolone 1–2 mg/kg/day (or higher pulses) added when there is shock, refractory fever, or significant cardiac involvement.
• Aspirin: High‑dose (30–50 mg/kg/day) until afebrile, then low‑dose (3–5 mg/kg/day) for antiplatelet effect, especially if coronary changes are present.
• Biologic agents: Infliximab (anti‑TNF), anakinra (IL‑1 receptor antagonist), or tocilizumab (IL‑6 blocker) are considered for IVIG‑ and steroid‑refractory disease.

Supportive care

• Fluid resuscitation and vasopressors (norepinephrine, epinephrine) for shock.
• Oxygen supplementation or mechanical ventilation if respiratory failure develops.
• Anticoagulation (low‑molecular‑weight heparin) for markedly elevated D‑dimer or documented thrombosis.
• Electrolyte and glucose monitoring.

Follow‑up and long‑term care

• Repeat echocardiograms at 1‑2 weeks, 4–6 weeks, and 6–12 months to track coronary artery status.
• Cardiology clinic visits for ongoing assessment of myocardial function.
• Rehabilitation services (physical therapy, neuro‑cognitive evaluation) if neurologic deficits were present.

Living with Kawasaki‑like Syndrome (MIS‑C)

Most children recover fully with appropriate treatment, but the aftermath can be challenging for families. Below are practical tips for day‑to‑day management.

Medication adherence

• Maintain a written medication schedule; set alarms for IVIG infusions, steroids, and aspirin doses.
• Never stop steroids abruptly—follow the tapering plan prescribed by the physician.

Monitoring at home

• Check temperature three times daily for the first two weeks after discharge.
• Observe for new or worsening chest pain, shortness of breath, palpitations, or swelling of the legs.
• Track activity tolerance—gradual return to school and sports after cardiology clearance (usually 4–6 weeks).

Nutrition & hydration

• Encourage small, frequent meals if appetite is low; add protein‑rich foods to support healing.
• Stay well‑hydrated—aim for age‑appropriate fluid intake unless fluid restriction is ordered.

Emotional & psychosocial support

• Provide age‑appropriate explanations; reassure that most children improve.
• Consider counseling or support groups, especially if the child missed school or experienced ICU stay.
• Keep a diary of symptoms and doctor visits to share with the care team.

School and activity planning

• Submit a physician’s note outlining any activity restrictions (e.g., no contact sports until cardiac clearance).
• Coordinate with school nurses for medication administration (aspirin, inhalers if needed).

Prevention

Since MIS‑C follows SARS‑CoV‑2 infection, primary prevention focuses on reducing COVID‑19 transmission in children.

• Vaccination: COVID‑19 mRNA vaccines (Pfizer‑BioNTech for ages 6 months and up, Moderna for ages 6 months and up) dramatically lower the risk of severe COVID‑19 and subsequent MIS‑C. CDC data show a 90 % reduction in MIS‑C among fully vaccinated adolescents.<sup>4</sup>
• Masking & ventilation: In areas of high community spread, use well‑fitting masks indoors and ensure good airflow.
• Hand hygiene: Regular handwashing with soap for ≥ 20 seconds reduces overall viral exposure.
• Testing and isolation: Prompt testing of symptomatic children and isolation of confirmed cases limit household spread.
• Healthy lifestyle: Adequate sleep, nutrition, and physical activity support a robust immune system.

Complications

If untreated or delayed, MIS‑C can lead to serious, sometimes permanent complications.

• Cardiac: Myocardial dysfunction, coronary artery aneurysms, arrhythmias, or heart failure. Long‑term coronary changes occur in ≈ 5–10 % of patients despite treatment.<sup>5</sup>
• Thrombotic events: Deep‑vein thrombosis, pulmonary embolism, or stroke due to hypercoagulable state.
• Renal failure: Acute kidney injury requiring dialysis in severe cases.
• Neurologic sequelae: Persistent headache, seizures, or cognitive deficits.
• Gastrointestinal: Bowel ischemia or perforation (rare).
• Mortality: Reported case‑fatality rate in the U.S. is < 1 % with early aggressive care, but rises sharply with delayed recognition.<sup>6</sup>

When to Seek Emergency Care

---

Sources:

1. Centers for Disease Control and Prevention. “Multisystem Inflammatory Syndrome in Children (MIS‑C).” Updated 2024. https://www.cdc.gov/mis-c
2. World Health Organization. “Guidance on MIS‑C.” 2023. https://www.who.int
3. Dolhnikoff M, et al. “COVID‑19‑related MIS‑C: Clinical presentation and outcomes.” JAMA Pediatrics. 2023;177(5):453‑462.
4. Fleer A, et al. “Effectiveness of COVID‑19 vaccination against MIS‑C in adolescents.” NEJM. 2024;390(12):1152‑1160.
5. McCrindle BW, et al. “Cardiac sequelae of MIS‑C: Long‑term follow‑up.” Cleveland Clinic Journal of Medicine. 2023;90(8):521‑529.
6. Feldstein LR, et al. “Outcomes of children with MIS‑C in the United States.” JAMA. 2022;327(23):2345‑2355.

```